Platinum Investment Management’s Coherus Oncology CHRS Stock Holding History

Platinum Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-549,899	Closed	-$3.76M	–	145
2023 Q1	$3.76M	Hold	549,899	–	–	0.13%	66
2022 Q4	$4.36M	Hold	549,899	–	–	0.17%	56
2022 Q3	$5.29M	Sell	549,899 -48,405	-8%	-$490K	0.22%	49
2022 Q2	$4.33M	Buy	598,304 +63,196	+12%	+$550K	0.16%	57
2022 Q1	$6.91M	Hold	535,108	–	–	0.21%	55
2021 Q4	$8.54M	Sell	535,108 -40,402	-7%	-$707K	0.24%	51
2021 Q3	$9.25M	Hold	575,510	–	–	0.26%	47
2021 Q2	$7.96M	Buy	575,510 +104,225	+22%	+$1.48M	0.18%	49
2021 Q1	$6.88M	Buy	471,285 +329,251	+232%	+$5.59M	0.15%	47
2020 Q4	$2.47M	Hold	142,034	–	–	0.06%	83
2020 Q3	$2.6M	Hold	142,034	–	–	0.06%	69
2020 Q2	$2.54M	Sell	142,034 -34,024	-19%	-$576K	0.06%	75
2020 Q1	$2.86M	Buy	176,058 +15,795	+10%	+$292K	0.07%	61
2019 Q4	$2.89M	Sell	160,263 -7,974	-5%	-$147K	0.06%	57
2019 Q3	$3.41M	Hold	168,237	–	–	0.08%	52
2019 Q2	$3.72M	Sell	168,237 -22,261	-12%	-$387K	0.09%	46
2019 Q1	$2.6M	Sell	190,498 -24,586	-11%	-$328K	0.06%	52
2018 Q4	$1.95M	Buy	215,084 +78,084	+57%	+$903K	0.07%	48
2018 Q3	$2.26M	Hold	137,000	–	–	0.06%	50
2018 Q2	$1.92M	Hold	137,000	–	–	0.05%	57
2018 Q1	$1.51M	Buy	137,000 +27,800	+25%	+$304K	0.04%	59
2017 Q4	$960K	Hold	109,200	–	–	0.03%	68
2017 Q3	$1.46M	Buy	+109,200	New	+$1.44M	0.04%	59

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Platinum Investment Management's CHRS Position: Q2 2023 in Review

Platinum Investment Management sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 549,899 shares — an estimated $3.76M sold.

Platinum Investment Management first reported a position in CHRS in Q3 2017 and held it in 23 quarters. The position peaked at $9.25M in Q3 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Platinum Investment Management reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
Platinum Investment Management sold 549,899 Coherus Oncology shares in Q2 2023, an estimated $3.76M.
Platinum Investment Management first reported a position in Coherus Oncology in Q3 2017 and held it in 23 quarters.
Platinum Investment Management's Coherus Oncology position peaked at $9.25M in Q3 2021.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Platinum Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.